利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

53 条记录 (耗时 0.024 秒)

    Modified Vaccinia virus Ankara for the vaccination of neonates
    6.
    发明申请
    Modified Vaccinia virus Ankara for the vaccination of neonates 审中-公开
    改良的痘苗病毒安卡拉用于接种新生儿

    公开(公告)号：US20060127984A1

    公开(公告)日：2006-06-15

    申请号：US11341955

    申请日：2006-01-27

    申请人： Mathias Ackermann ,  Mark Suter ,  Hans Hefti ,  Marco Franchini ,  Sabine Vollstedt ,  Paul Chaplin

    发明人： Mathias Ackermann ,  Mark Suter ,  Hans Hefti ,  Marco Franchini ,  Sabine Vollstedt ,  Paul Chaplin

    IPC分类号： C12Q1/68 ,  C12P21/06

    CPC分类号： A61K45/06 ,  A61K39/12 ,  A61K39/245 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/55 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16643 ,  C12N2710/24134 ,  C12N2710/24143

    摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

    摘要翻译： 本发明涉及病毒用于制备用于疫苗接种或治疗新生儿或产前动物（包括人）的药物，其中病毒能感染新生儿或产前动物（包括人）的细胞， 但不能在新生儿或产前动物（包括人）中复制感染性后代病毒。 病毒优选为修饰的痘苗病毒安卡拉。 特别地，本发明涉及新生儿针对与用于接种疫苗的病毒相同的病毒组的病毒感染的疫苗接种。 此外，本发明涉及新生儿针对选自外源抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明还涉及如上定义的病毒的使用以增加激活树突状细胞或其前体细胞的因子水平和/或增加树突状细胞或其前体细胞的数量和/或增加生产和/或细胞 干扰素（IFN）或IL-12的含量。

    Modified vaccinia virus ankara for the vaccination of neonates
    8.
    发明授权
    Modified vaccinia virus ankara for the vaccination of neonates 有权
    改良的痘苗病毒安卡拉用于接种新生儿

    公开(公告)号：US07097842B2

    公开(公告)日：2006-08-29

    申请号：US10418854

    申请日：2003-04-18

    申请人： Mark Suter ,  Sabine Vollstedt ,  Paul Chaplin

    发明人： Mark Suter ,  Sabine Vollstedt ,  Paul Chaplin

    IPC分类号： A61K39/285 ,  C12N7/00 ,  C12N7/01 ,  C12N7/04 ,  C12N15/863

    CPC分类号： A61K45/06 ,  A61K39/12 ,  A61K39/245 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/55 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16643 ,  C12N2710/24134 ,  C12N2710/24143

    摘要： The invention concerns the use of a virus for the preparation of a medicament for the vaccination, treatment, or protection, of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group as the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumor antigens, wherein the tumor antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to (i) increase the level of factors which activate dendritic cells or their precursor cells, (ii) and/or to increase the number of dendritic cells or their precursor cells, (iii) and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

    摘要翻译： 本发明涉及病毒用于制备用于疫苗接种，治疗或保护新生儿或产前动物（包括人）的药物的用途，其中所述病毒能够感染新生儿或产前动物的细胞， 包括人，但不能在新生儿或产前动物（包括人）中复制感染性后代病毒。 病毒优选为修饰的痘苗病毒安卡拉。 特别地，本发明涉及新生儿针对与用于接种疫苗的病毒相同的病毒组的病毒感染的接种。 此外，本发明涉及新生儿针对选自外源抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明还涉及如上定义的病毒的使用，以（i）增加激活树突细胞或其前体细胞的因子水平，（ii）和/或增加树突状细胞或其前体细胞的数量，（iii） 和/或增加干扰素（IFN）或IL-12的产生和/或细胞含量。

    MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES
    10.
    发明申请
    MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES 有权
    改良的VACCINIA VIRUS ANKARA用于接种新生儿

    公开(公告)号：US20090104224A1

    公开(公告)日：2009-04-23

    申请号：US12118841

    申请日：2008-05-12

    申请人： Mathias Ackermann ,  Mark Suter ,  Hans Peter Hefti ,  Marco Franchini ,  Sabine Vollstedt ,  Paul Chaplin

    发明人： Mathias Ackermann ,  Mark Suter ,  Hans Peter Hefti ,  Marco Franchini ,  Sabine Vollstedt ,  Paul Chaplin

    IPC分类号： A61K35/76 ,  A61P37/04

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

    摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

    摘要翻译： 本发明涉及病毒用于制备用于疫苗接种或治疗新生儿或产前动物（包括人）的药物，其中病毒能感染新生儿或产前动物（包括人）的细胞， 但不能在新生儿或产前动物（包括人）中复制感染性后代病毒。 病毒优选为修饰的痘苗病毒安卡拉。 特别地，本发明涉及新生儿针对与用于接种疫苗的病毒相同的病毒组的病毒感染的疫苗接种。 此外，本发明涉及新生儿针对选自外源抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明还涉及如上定义的病毒的使用以增加激活树突状细胞或其前体细胞的因子水平和/或增加树突状细胞或其前体细胞的数量和/或增加生产和/或细胞 干扰素（IFN）或IL-12的含量。